

The National Expert Group for tixagevimab/cilgavimab (Evusheld) pre-exposure prophylaxis of COVID-19

19 May 2022 14:00-15:30

Attendees

Professor Anthony Kessel (Chair) (AK)	Clinical Director, National Clinical Policy, NHS England and NHS Improvement
	██████████ Liverpool School of Tropical Medicine
	██████████ UK Health Security Agency (UKHSA)
	██████████, UKHSA
	██████████, University of Liverpool
	██████████, Alder Hey Children's Hospital
	██████████, Royal Free Hospital
	██████████ NIHR Clinical Research Network
	██████████, The Newcastle Upon Tyne Hospitals NHS Foundation Trust
	██████████ Chelsea and Westminster Hospital
	██████████ Welsh Government
	██████████, University of Glasgow
	██████████, NICE
	██████████, UKHSA
	Department of Health, Northern Ireland
	██████████ Welsh Government
	██████████ The Scottish Government
	██████████ Welsh Government
	Member of the COVID-19 Prophylaxis Oversight Group
	Department of Health and Social Care Observer
	Department of Health and Social Care Observer
	██████████ NHS England and NHS Improvement
	██████████ NHS England and NHS Improvement
	██████████ NHS England and NHS Improvement
	██████████ NHS England and NHS Improvement
	██████████ NHS England and NHS Improvement

The National Expert Group for tixagevimab/cilgavimab (Evusheld) pre-exposure prophylaxis of COVID-19
26 April 2022 10:00-11:30
Via Teams
NOTES OF MEETING

Attendees

Professor Anthony Kessel (Chair) (AK)	Clinical Director, National Clinical Policy, NHS England and NHS Improvement
	Alder Hey Children's Hospital
	UCLH NHS Foundation Trust
	Royal Free Hospital
	University of Liverpool
	University of Liverpool
	University of Glasgow
	Welsh Government
	The Newcastle Upon Tyne Hospitals NHS Foundation Trust
	Crick Institute
	UKHSA
	University of Oxford
	North Bristol NHS Trust
	Department of Health, Northern Ireland
	Department of Health, Northern Ireland
	Welsh Government
	The Scottish Government
	Welsh Government
	Department of Health & Social Care
Professor James Palmer (JP)	National Medical Director, Specialised Commissioning, NHS England and Improvement
	NHS England and NHS Improvement
	NHS England and NHS Improvement
	NHS England and NHS Improvement
	NHS England and NHS Improvement
	NHS England and NHS Improvement

The Access and Policy National Expert Working Group for Neutralising Monoclonal Antibodies
10th November 2021 16:00-17:30

Via Teams
NOTES OF MEETING

Attendees

Professor James Palmer (Chair) (JP)	National Medical Director, Specialised Commissioning, NHS England and Improvement
Professor Anthony Kessel (AK)	Clinical Director, National Clinical Policy, NHS England and NHS Improvement
[REDACTED]	[REDACTED] Crick Institute
[REDACTED]	[REDACTED] Welsh Government
[REDACTED]	[REDACTED] The Newcastle Upon Tyne Hospitals NHS Foundation Trust
[REDACTED]	[REDACTED] The Scottish Government
[REDACTED]	[REDACTED] NHS England and NHS Improvement
[REDACTED]	[REDACTED] Royal Free Hospital
[REDACTED]	[REDACTED] UKHSA [REDACTED]
[REDACTED]	[REDACTED] University of Oxford
[REDACTED]	[REDACTED] NHS England and NHS Improvement
[REDACTED]	[REDACTED] NHS England and NHS Improvement